P667: LONG-TERM EFFICACY OF ACALABRUTINIB-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND HIGHER-RISK GENOMIC FEATURES: POOLED ANALYSIS OF CLINICAL TRIAL DATA

• M. Davids,
• J. Sharman,
• P. Ghia,
• J. Woyach,
• W. Jurczak,
• T. Siddiqi,
• P. Miranda,
• M. Shahkarami,
• T. Yu,
• U. Emeribe,
• J. Byrd

Affiliations

M. Davids

1 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts

J. Sharman

2 Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States of America

P. Ghia

3 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy

J. Woyach

4 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States of America

W. Jurczak

5 Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland

T. Siddiqi

6 City of Hope Comprehensive Cancer Center, Duarte, California

P. Miranda

7 AstraZeneca, Gaithersburg, Maryland

M. Shahkarami

8 AstraZeneca, South San Francisco, California

T. Yu

8 AstraZeneca, South San Francisco, California

U. Emeribe

7 AstraZeneca, Gaithersburg, Maryland

J. Byrd

9 Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America